Lactobacillus delbrueckii CIDCA 133 Ameliorates Chemotherapy-Induced Mucositis by Modulating Epithelial Barrier and TLR2/4/Myd88/NF-κB Signaling Pathway
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2022 |
| Outros Autores: | , , , , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da UFMG |
| Texto Completo: | https://doi.org/10.3389/fmicb.2022.858036 http://hdl.handle.net/1843/60508 https://orcid.org/0000-0002-1835-0303 |
Resumo: | Intestinal mucositis promoted by the use of anticancer drugs is characterized by ulcerative inflammation of the intestinal mucosa, a debilitating side effect in cancer patients undergoing treatment. Probiotics are a potential therapeutic option to alleviate intestinal mucositis due to their effects on epithelial barrier integrity and anti-inflammatory modulation. This study investigated the health-promoting impact of Lactobacillus delbrueckii CIDCA 133 in modulating inflammatory and epithelial barrier markers to protect the intestinal mucosa from 5-fluorouracil-induced epithelial damage. L. delbrueckii CIDCA 133 consumption ameliorated small intestine shortening, inflammatory cell infiltration, intestinal permeability, villus atrophy, and goblet cell count, improving the intestinal mucosa architecture and its function in treated mice. Upregulation of Muc2, Cldn1, Hp, F11r, and Il10, and downregulation of markers involved in NF-κB signaling pathway activation (Tlr2, Tlr4, Nfkb1, Il6, and Il1b) were observed at the mRNA level. This work suggests a beneficial role of L. delbrueckii strain CIDCA 133 on intestinal damage induced by 5-FU chemotherapy through modulation of inflammatory pathways and improvement of epithelial barrier function. |
| id |
UFMG_181d4c1e3884f6bf034ffb068b9b54df |
|---|---|
| oai_identifier_str |
oai:repositorio.ufmg.br:1843/60508 |
| network_acronym_str |
UFMG |
| network_name_str |
Repositório Institucional da UFMG |
| repository_id_str |
|
| spelling |
Lactobacillus delbrueckii CIDCA 133 Ameliorates Chemotherapy-Induced Mucositis by Modulating Epithelial Barrier and TLR2/4/Myd88/NF-κB Signaling PathwayMucositeTumoresProbióticosTratamento FarmacológicoMucositeTumoresProbióticosTratamento FarmacológicoIntestinal mucositis promoted by the use of anticancer drugs is characterized by ulcerative inflammation of the intestinal mucosa, a debilitating side effect in cancer patients undergoing treatment. Probiotics are a potential therapeutic option to alleviate intestinal mucositis due to their effects on epithelial barrier integrity and anti-inflammatory modulation. This study investigated the health-promoting impact of Lactobacillus delbrueckii CIDCA 133 in modulating inflammatory and epithelial barrier markers to protect the intestinal mucosa from 5-fluorouracil-induced epithelial damage. L. delbrueckii CIDCA 133 consumption ameliorated small intestine shortening, inflammatory cell infiltration, intestinal permeability, villus atrophy, and goblet cell count, improving the intestinal mucosa architecture and its function in treated mice. Upregulation of Muc2, Cldn1, Hp, F11r, and Il10, and downregulation of markers involved in NF-κB signaling pathway activation (Tlr2, Tlr4, Nfkb1, Il6, and Il1b) were observed at the mRNA level. This work suggests a beneficial role of L. delbrueckii strain CIDCA 133 on intestinal damage induced by 5-FU chemotherapy through modulation of inflammatory pathways and improvement of epithelial barrier function.CNPq - Conselho Nacional de Desenvolvimento Científico e TecnológicoUniversidade Federal de Minas GeraisBrasilFAR - DEPARTAMENTO DE ALIMENTOSFAR - DEPARTAMENTO DE ANÁLISES CLÍNICAS E TOXICOLÓGICASFARMACIA - FACULDADE DE FARMACIAICB - DEPARTAMENTO DE MICROBIOLOGIAICB - DEPARTAMENTO DE PATOLOGIAUFMG2023-11-06T20:29:56Z2023-11-06T20:29:56Z2022info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlepdfapplication/pdfhttps://doi.org/10.3389/fmicb.2022.8580361664-302Xhttp://hdl.handle.net/1843/60508https://orcid.org/0000-0002-1835-0303engFrontiers in MicrobiologyFernanda Alvarenga Lima BarrosoEnio FerreiraFlaviano Dos Santos MartinsMariana Martins DrumondPamela Mancha-agrestiAlexander BirbrairDebmalya BarhVasco AzevedoLuís Cláudio Lima de JesusTales Fernando da SilvaViviane Lima BatistaJuliana LagunaNina Dias Coelho-RochaKátia Duarte VitalSimone Odília Antunes FernandesValbert Nascimento Cardosoinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFMGinstname:Universidade Federal de Minas Gerais (UFMG)instacron:UFMG2023-11-06T20:29:56Zoai:repositorio.ufmg.br:1843/60508Repositório InstitucionalPUBhttps://repositorio.ufmg.br/oairepositorio@ufmg.bropendoar:2023-11-06T20:29:56Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)false |
| dc.title.none.fl_str_mv |
Lactobacillus delbrueckii CIDCA 133 Ameliorates Chemotherapy-Induced Mucositis by Modulating Epithelial Barrier and TLR2/4/Myd88/NF-κB Signaling Pathway |
| title |
Lactobacillus delbrueckii CIDCA 133 Ameliorates Chemotherapy-Induced Mucositis by Modulating Epithelial Barrier and TLR2/4/Myd88/NF-κB Signaling Pathway |
| spellingShingle |
Lactobacillus delbrueckii CIDCA 133 Ameliorates Chemotherapy-Induced Mucositis by Modulating Epithelial Barrier and TLR2/4/Myd88/NF-κB Signaling Pathway Fernanda Alvarenga Lima Barroso Mucosite Tumores Probióticos Tratamento Farmacológico Mucosite Tumores Probióticos Tratamento Farmacológico |
| title_short |
Lactobacillus delbrueckii CIDCA 133 Ameliorates Chemotherapy-Induced Mucositis by Modulating Epithelial Barrier and TLR2/4/Myd88/NF-κB Signaling Pathway |
| title_full |
Lactobacillus delbrueckii CIDCA 133 Ameliorates Chemotherapy-Induced Mucositis by Modulating Epithelial Barrier and TLR2/4/Myd88/NF-κB Signaling Pathway |
| title_fullStr |
Lactobacillus delbrueckii CIDCA 133 Ameliorates Chemotherapy-Induced Mucositis by Modulating Epithelial Barrier and TLR2/4/Myd88/NF-κB Signaling Pathway |
| title_full_unstemmed |
Lactobacillus delbrueckii CIDCA 133 Ameliorates Chemotherapy-Induced Mucositis by Modulating Epithelial Barrier and TLR2/4/Myd88/NF-κB Signaling Pathway |
| title_sort |
Lactobacillus delbrueckii CIDCA 133 Ameliorates Chemotherapy-Induced Mucositis by Modulating Epithelial Barrier and TLR2/4/Myd88/NF-κB Signaling Pathway |
| author |
Fernanda Alvarenga Lima Barroso |
| author_facet |
Fernanda Alvarenga Lima Barroso Enio Ferreira Flaviano Dos Santos Martins Mariana Martins Drumond Pamela Mancha-agresti Alexander Birbrair Debmalya Barh Vasco Azevedo Luís Cláudio Lima de Jesus Tales Fernando da Silva Viviane Lima Batista Juliana Laguna Nina Dias Coelho-Rocha Kátia Duarte Vital Simone Odília Antunes Fernandes Valbert Nascimento Cardoso |
| author_role |
author |
| author2 |
Enio Ferreira Flaviano Dos Santos Martins Mariana Martins Drumond Pamela Mancha-agresti Alexander Birbrair Debmalya Barh Vasco Azevedo Luís Cláudio Lima de Jesus Tales Fernando da Silva Viviane Lima Batista Juliana Laguna Nina Dias Coelho-Rocha Kátia Duarte Vital Simone Odília Antunes Fernandes Valbert Nascimento Cardoso |
| author2_role |
author author author author author author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Fernanda Alvarenga Lima Barroso Enio Ferreira Flaviano Dos Santos Martins Mariana Martins Drumond Pamela Mancha-agresti Alexander Birbrair Debmalya Barh Vasco Azevedo Luís Cláudio Lima de Jesus Tales Fernando da Silva Viviane Lima Batista Juliana Laguna Nina Dias Coelho-Rocha Kátia Duarte Vital Simone Odília Antunes Fernandes Valbert Nascimento Cardoso |
| dc.subject.por.fl_str_mv |
Mucosite Tumores Probióticos Tratamento Farmacológico Mucosite Tumores Probióticos Tratamento Farmacológico |
| topic |
Mucosite Tumores Probióticos Tratamento Farmacológico Mucosite Tumores Probióticos Tratamento Farmacológico |
| description |
Intestinal mucositis promoted by the use of anticancer drugs is characterized by ulcerative inflammation of the intestinal mucosa, a debilitating side effect in cancer patients undergoing treatment. Probiotics are a potential therapeutic option to alleviate intestinal mucositis due to their effects on epithelial barrier integrity and anti-inflammatory modulation. This study investigated the health-promoting impact of Lactobacillus delbrueckii CIDCA 133 in modulating inflammatory and epithelial barrier markers to protect the intestinal mucosa from 5-fluorouracil-induced epithelial damage. L. delbrueckii CIDCA 133 consumption ameliorated small intestine shortening, inflammatory cell infiltration, intestinal permeability, villus atrophy, and goblet cell count, improving the intestinal mucosa architecture and its function in treated mice. Upregulation of Muc2, Cldn1, Hp, F11r, and Il10, and downregulation of markers involved in NF-κB signaling pathway activation (Tlr2, Tlr4, Nfkb1, Il6, and Il1b) were observed at the mRNA level. This work suggests a beneficial role of L. delbrueckii strain CIDCA 133 on intestinal damage induced by 5-FU chemotherapy through modulation of inflammatory pathways and improvement of epithelial barrier function. |
| publishDate |
2022 |
| dc.date.none.fl_str_mv |
2022 2023-11-06T20:29:56Z 2023-11-06T20:29:56Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.uri.fl_str_mv |
https://doi.org/10.3389/fmicb.2022.858036 1664-302X http://hdl.handle.net/1843/60508 https://orcid.org/0000-0002-1835-0303 |
| url |
https://doi.org/10.3389/fmicb.2022.858036 http://hdl.handle.net/1843/60508 https://orcid.org/0000-0002-1835-0303 |
| identifier_str_mv |
1664-302X |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
Frontiers in Microbiology |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
pdf application/pdf |
| dc.publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais Brasil FAR - DEPARTAMENTO DE ALIMENTOS FAR - DEPARTAMENTO DE ANÁLISES CLÍNICAS E TOXICOLÓGICAS FARMACIA - FACULDADE DE FARMACIA ICB - DEPARTAMENTO DE MICROBIOLOGIA ICB - DEPARTAMENTO DE PATOLOGIA UFMG |
| publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais Brasil FAR - DEPARTAMENTO DE ALIMENTOS FAR - DEPARTAMENTO DE ANÁLISES CLÍNICAS E TOXICOLÓGICAS FARMACIA - FACULDADE DE FARMACIA ICB - DEPARTAMENTO DE MICROBIOLOGIA ICB - DEPARTAMENTO DE PATOLOGIA UFMG |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFMG instname:Universidade Federal de Minas Gerais (UFMG) instacron:UFMG |
| instname_str |
Universidade Federal de Minas Gerais (UFMG) |
| instacron_str |
UFMG |
| institution |
UFMG |
| reponame_str |
Repositório Institucional da UFMG |
| collection |
Repositório Institucional da UFMG |
| repository.name.fl_str_mv |
Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG) |
| repository.mail.fl_str_mv |
repositorio@ufmg.br |
| _version_ |
1823248191720521728 |